Most Read Articles
Pearl Toh, 4 days ago
First-line therapy with the BTK* inhibitor ibrutinib plus the anti-CD20 immunotherapy rituximab confers significant survival advantage over the current gold-standard regimen of fludarabine, cyclophosphamide, and rituximab (FCR) for young, fit patients with treatment-naïve chronic lymphocytic leukaemia (CLL), according to the E1912 trial, a large cooperative group study supported by the US National Cancer Institute.
Rachel Soon, 05 Dec 2018

At the recent Malaysian Community Pharmacy Business Forum (MyCPBF), a discussion forum was held on the subject of “Transcending Primary Healthcare Services: The Future of Specialized Pharmacy Services and Pharmacy Specialization”.

Dr Renly Lim, 01 Aug 2018
Palliative care uses an integrated, multidisciplinary approach to reduce suffering and to improve the quality of life of patients battling with life-threatening illnesses.
Audrey Abella, 28 Nov 2018
Use of the oral anticoagulant rivaroxaban at a low dose may reduce the risk of thromboembolic events* in patients with heart failure (HF), according to a post hoc analysis of the COMMANDER HF** trial.

Repeated vaccination effective in protecting against severe influenza

09 Jan 2018

Repeated influenza vaccination is effective in preventing severe vs nonsevere influenza infections in elderly adults, a recent multicentre, case-control study has shown.

The study included 130 and 598 patients with severe and nonsevere influenza, who were then matched to 333 and 1,493 controls, respectively.

Vaccination in the current season and at least one of the three previous seasons led to significantly lower odds of severe disease (adjusted odds ratio [OR], 0.45; 95 percent CI, 0.26–0.76; p=0.003), intensive care unit (ICU) admission (adjusted OR, 0.35; 0.17–0.70; p=0.003) and death (adjusted OR, 0.44; 0.23–0.86; p=0.02).

In comparison, those who were only vaccinated in the current season did not reduce risks of severe disease (adjusted OR, 2.22; 0.89–5.51; p=0.09) and ICU admissions (adjusted OR, 1.14; 0.34–3.87; p=0.8), and had significantly higher risk of death (adjusted OR, 3.35; 1.06–10.58; p=0.04).

Moreover, those who were unvaccinated were admitted to the ICU more frequently (16 vs 6 percent; p<0.001) compared with those who were vaccinated. Mortality rates within the first 30 days after admission were also higher in unvaccinated participants (14 vs 9 percent; p=0.04).

In terms of hospital admissions, those who were vaccinated in the current season and in any of the three previous seasons were less likely to be admitted to the hospital for nonsevere influenza (31 percent effectiveness). Effectiveness estimates were higher for preventing ICU admission (74 percent) and death (70 percent).

Furthermore, those who were vaccinated in the current season only were not significantly protected against severe influenza.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 4 days ago
First-line therapy with the BTK* inhibitor ibrutinib plus the anti-CD20 immunotherapy rituximab confers significant survival advantage over the current gold-standard regimen of fludarabine, cyclophosphamide, and rituximab (FCR) for young, fit patients with treatment-naïve chronic lymphocytic leukaemia (CLL), according to the E1912 trial, a large cooperative group study supported by the US National Cancer Institute.
Rachel Soon, 05 Dec 2018

At the recent Malaysian Community Pharmacy Business Forum (MyCPBF), a discussion forum was held on the subject of “Transcending Primary Healthcare Services: The Future of Specialized Pharmacy Services and Pharmacy Specialization”.

Dr Renly Lim, 01 Aug 2018
Palliative care uses an integrated, multidisciplinary approach to reduce suffering and to improve the quality of life of patients battling with life-threatening illnesses.
Audrey Abella, 28 Nov 2018
Use of the oral anticoagulant rivaroxaban at a low dose may reduce the risk of thromboembolic events* in patients with heart failure (HF), according to a post hoc analysis of the COMMANDER HF** trial.